Rhone-Poulenc Rorer's Granocyte Perhaps More Potent Than Neupogen

18 December 1995

- Rhone-Poulenc Rorer's granulocyte colony stimulating factor drug Granocyte (lenograstim) may be 25% more potent than Amgen-Roche's Neupogen (filgrastim) in mobilizing stem cells for peripheral blood transplantation, according to data presented at the American Society of Hematology meeting earlier this month. "More potent mobilization implies that more blood stem cells may be collected within a shorter period of time," said principal investigator Martin Hoglund, of the University Hospital of Uppsala, Sweden.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight